- Home
- ACHC vs HALO Comparison
ACHC vs HALO Comparison
Compare ACHC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | HALO |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 7.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACHC | HALO |
|---|---|---|
| Price | $14.43 | $67.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | $24.00 | ★ $73.33 |
| AVG Volume (30 Days) | ★ 3.6M | 2.6M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.68 |
| EPS | 1.18 | ★ 4.74 |
| Revenue | ★ $3,265,548,000.00 | $1,242,852,000.00 |
| Revenue This Year | $6.50 | $34.83 |
| Revenue Next Year | $4.38 | $24.84 |
| P/E Ratio | ★ $12.22 | $14.22 |
| Revenue Growth | 4.58 | ★ 31.19 |
| 52 Week Low | $12.63 | $46.26 |
| 52 Week High | $47.08 | $79.50 |
Technical Indicators
Market Signals| Indicator | ACHC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 54.13 |
| Support Level | $13.95 | $61.23 |
| Resistance Level | $14.94 | $66.60 |
| Average True Range (ATR) | 0.85 | 2.03 |
| MACD | 0.21 | 0.28 |
| Stochastic Oscillator | 42.35 | 81.90 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.